SPDR S&P Biotech ETF Rating $86.07 -0.20 (-0.23%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock SPDR S&P Biotech ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.74Holdings in XBI have an aggregate rating of Moderate Buy based on 765 analyst ratings issued in the past year covering 50 companies (78.1% of the portfolio).XBI Aggregate Price Target$86.07High Prediction$86.07Average Prediction$86.07Low Prediction$86.07Holdings in XBI have an aggregate price target of $86.07 and a range of $86.07 to $86.07 covering 50 companies (78.1% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy16 Buy rating(s)Moderate Buy26 Moderate Buy rating(s)Hold8 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 XBI Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings3.53%INSMInsmed$102.92+0.4%3.957 of 5 stars3.00$108.47 5.4%17Positive News3.25%ALNYAlnylam Pharmaceuticals$321.01+0.1%4.0191 of 5 stars2.81$347.75 8.3%26Analyst Forecast3.03%NTRANatera$140.44+1.1%2.7675 of 5 stars3.00$184.63 31.5%15Positive News3.00%BPMCBlueprint Medicines$129.460.9769 of 5 stars2.24$128.25 -0.9%21Analyst Upgrade2.95%NBIXNeurocrine Biosciences$131.960.0%4.4652 of 5 stars2.88$163.87 24.2%24Analyst Forecast2.91%EXASExact Sciences$48.46-4.0%4.7321 of 5 stars2.95$70.50 45.5%22Positive News2.57%INCYIncyte$67.31-0.8%4.8225 of 5 stars2.22$74.47 10.6%182.42%GILDGilead Sciences$108.62+0.4%4.914 of 5 stars2.77$111.38 2.5%262.41%UTHRUnited Therapeutics$293.09+0.4%4.9854 of 5 stars2.69$383.08 30.7%13Positive News2.36%AMGNAmgen$295.33+0.2%4.4075 of 5 stars2.35$308.32 4.4%23Positive NewsAnalyst Forecast2.31%BIIBBiogen$122.79-1.8%4.9294 of 5 stars2.34$186.37 51.8%32Trending NewsAnalyst Forecast2.27%VRTXVertex Pharmaceuticals$459.700.0%4.7249 of 5 stars2.54$511.71 11.3%28Positive News2.23%ABBVAbbVie$185.39-2.0%4.8256 of 5 stars2.81$211.29 14.0%27Positive News2.19%EXELExelixis$44.42-0.1%4.8201 of 5 stars2.52$45.28 1.9%212.01%MDGLMadrigal Pharmaceuticals$329.83-1.3%4.2708 of 5 stars2.89$420.63 27.5%9Insider Trade1.99%BBIOBridgeBio Pharma$46.11-0.9%4.5394 of 5 stars3.00$61.50 33.4%16Analyst Forecast1.88%MRNAModerna$31.38+0.4%4.2562 of 5 stars2.04$46.61 48.5%251.88%REGNRegeneron Pharmaceuticals$547.60+0.9%4.8326 of 5 stars2.80$814.57 48.8%25Positive News1.70%BMRNBioMarin Pharmaceutical$56.70-1.0%4.9877 of 5 stars2.75$93.78 65.4%24Positive NewsAnalyst DowngradeAnalyst Revision1.55%IONSIonis Pharmaceuticals$41.82+0.1%4.4562 of 5 stars2.76$57.13 36.6%17Analyst Revision1.54%TGTXTG Therapeutics$37.63-0.7%3.6958 of 5 stars2.80$43.80 16.4%5Positive News1.53%RVMDRevolution Medicines$38.45+0.4%4.5594 of 5 stars3.00$68.91 79.2%111.52%CRSPCRISPR Therapeutics$66.76+2.5%1.976 of 5 stars2.53$71.75 7.5%17Analyst RevisionGap UpHigh Trading Volume1.38%HALOHalozyme Therapeutics$55.78-1.2%4.9616 of 5 stars2.17$62.70 12.4%12Positive News1.34%ROIVRoivant Sciences$11.53+0.7%2.8219 of 5 stars3.25$16.50 43.2%4Positive News1.23%SWTXSpringWorks Therapeutics$46.991.5152 of 5 stars2.13$52.57 11.9%8Positive News1.13%CYTKCytokinetics$36.87-1.0%4.1043 of 5 stars2.93$70.92 92.4%15News Coverage1.13%VKTXViking Therapeutics$32.30+0.9%4.6133 of 5 stars3.00$87.15 169.8%14Upcoming Earnings1.11%SMMTSummit Therapeutics$26.47+1.0%3.217 of 5 stars2.79$34.67 31.0%141.07%ACADACADIA Pharmaceuticals$22.39-0.8%4.4751 of 5 stars2.71$27.88 24.5%171.03%ALKSAlkermes$26.99-7.6%4.7873 of 5 stars2.83$40.92 51.6%12Analyst ForecastHigh Trading Volume1.02%PCVXVaxcyte$35.91-0.8%1.8438 of 5 stars3.10$136.50 280.2%10Positive News1.00%RNAAvidity Biosciences$34.32+1.6%2.5127 of 5 stars3.06$66.35 93.4%17Positive News0.95%AKROAkero Therapeutics$51.66-0.8%3.6594 of 5 stars3.00$82.50 59.7%6Insider Trade0.93%ADMAADMA Biologics$17.11+2.3%3.8714 of 5 stars3.33$27.67 61.7%3Positive News0.90%SRRKScholar Rock$41.15+1.0%3.1304 of 5 stars3.13$42.67 3.7%8Insider TradeAnalyst Revision0.90%NUVLNuvalent$83.00-0.5%3.3579 of 5 stars3.17$119.60 44.1%120.87%ACLXArcellx$69.42+2.7%2.5457 of 5 stars3.07$111.23 60.2%15Positive News0.87%SLNOSoleno Therapeutics$87.32+0.1%4.2843 of 5 stars3.09$108.70 24.5%11Positive NewsAnalyst Revision0.84%RYTMRhythm Pharmaceuticals$88.19-1.1%3.2003 of 5 stars3.07$91.93 4.2%15Analyst Forecast0.81%TWSTTwist Bioscience$34.79-1.1%4.3234 of 5 stars2.70$50.40 44.9%100.78%RAREUltragenyx Pharmaceutical$26.59+1.1%4.379 of 5 stars2.93$83.64 214.6%14High Trading Volume0.76%AGIOAgios Pharmaceuticals$40.27+0.7%4.3998 of 5 stars2.71$58.60 45.5%70.75%KRYSKrystal Biotech$148.90+1.0%4.5451 of 5 stars3.00$213.75 43.6%90.75%APLSApellis Pharmaceuticals$19.43-0.2%4.3324 of 5 stars2.62$40.00 105.9%21Analyst ForecastInsider Trade0.73%CRNXCrinetics Pharmaceuticals$31.00-0.3%3.5401 of 5 stars2.80$69.50 124.2%10Positive News0.71%RXRXRecursion Pharmaceuticals$6.46+10.5%0.697 of 5 stars2.33$7.00 8.4%6Analyst RevisionGap UpHigh Trading Volume0.70%ARWRArrowhead Pharmaceuticals$14.83-11.5%3.812 of 5 stars2.75$43.71 194.9%8Positive NewsAnalyst DowngradeHigh Trading Volume0.69%VCYTVeracyte$23.06-1.9%3.7765 of 5 stars2.70$40.90 77.4%100.68%PTCTPTC Therapeutics$48.02+0.8%4.3511 of 5 stars2.67$65.00 35.3%15 This page (NYSEARCA:XBI) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
